Rivaroxaban Tablet, Film Coated
NDC Package 62332-348-90
Package Information
Rivaroxaban tablets is rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. This formulation utilizes a tablet, film coated delivery system. Marketed by Alembic Pharmaceuticals Inc., this product is identified by NDC 62332-348 and is authorized under FDA application ANDA210301.
Identification & Billing
- RxCUI: 1114198 - rivaroxaban 10 MG Oral Tablet
- RxCUI: 1232082 - rivaroxaban 15 MG Oral Tablet
- RxCUI: 1232086 - rivaroxaban 20 MG Oral Tablet
- RxCUI: 1549682 - {42 (rivaroxaban 15 MG Oral Tablet) / 9 (rivaroxaban 20 MG Oral Tablet) } Pack
- RxCUI: 1549682 - rivaroxaban 30-Day Starter Pack (42-15 MG Oral Tablets & 9-20 MG Oral Tablets)
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 62332 - Alembic Pharmaceuticals Inc.
- 62332-348 - Rivaroxaban
- 62332-348-90 - 90 TABLET, FILM COATED in 1 BOTTLE
- 62332-348 - Rivaroxaban
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (62332-348). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 62332-348-90 identifies a specific commercial package of 90 tablet, film coated in 1 bottle of Rivaroxaban, a human prescription drug labeled by Alembic Pharmaceuticals Inc.. This tablet, film coated is formulated for oral use and contains rivaroxaban as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Alembic Pharmaceuticals Inc. on May 14, 2025. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.
How is this Alembic Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 62332034890. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
